Please find attached Safety Communication from Wyeth Pharmaceuticals on the association of InductOs (dibotermin alfa) with reports of fluid collections (e.g. pseudocysts, localised oedema, implant site effusion) sometimes encapsulated, in patients receiving InductOs for spinal procedures, regularly requiring intervention.